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The incidence of fungal infections has been increasing in the last decades, while the
number of available antifungal classes remains the same. The natural and acquired
resistance of some fungal species to available therapies, associated with the high
toxicity of these drugs on the present scenario and makes an imperative of the
search for new, more efficient and less toxic therapeutic choices. Antimicrobial
peptides (AMPs) are a potential class of antimicrobial drugs consisting of evolutionarily
conserved multifunctional molecules with both microbicidal and immunomodulatory
properties being part of the innate immune response of diverse organisms. In this
study, we evaluated 11 scorpion-venom derived non-disulfide-bridged peptides against
Cryptococcus neoformans and Candida spp., which are important human pathogens.
Seven of them, including two novel molecules, showed activity against both genera with
minimum inhibitory concentration values ranging from 3.12 to 200 µM and an analogous
activity against Candida albicans biofilms. Most of the peptides presented low hemolytic
and cytotoxic activity against mammalian cells. Modifications in the primary peptide
sequence, as revealed by in silico and circular dichroism analyses of the most promising
peptides, underscored the importance of cationicity for their antimicrobial activity as
well as the amphipathicity of these molecules and their tendency to form alpha helices.
This is the first report of scorpion-derived AMPs against C. neoformans and our
results underline the potential of scorpion venom as a source of antimicrobials. Further
characterization of their mechanism of action, followed by molecular optimization to
decrease their cytotoxicity and increase antimicrobial activity, is needed to fully clarify
their real potential as antifungals.
Keywords: antifungal drugs, antimicrobial peptides, Candida spp., Candida albicans, Cryptococcus neoformans,
scorpions venom
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INTRODUCTION
An increase of systemic mycoses incidence due to the
rising number of immunocompromised individuals, particularly
cancer, HIV/AIDS and solid-organ transplant patients has been
noticed in recent years. Candida spp. and Cryptococcus spp. are
among the main causative agents (Romani, 2011; Armstrong-
James et al., 2014).
Candida spp. remain the most important cause of
opportunistic mycoses worldwide and are associated to
high mortality and morbidity rates, Candida albicans being
the major agent of candidemia (Pfaller and Diekema, 2007;
Mikulska et al., 2012). Furthermore, an increase in infections
caused by non-albicans species has been noticed, like Candida
parapsilosis, Candida tropicalis, and Candida glabrata, the latter
being more resistant to antifungal drugs than other Candida
species (Sobel, 2006; Pfaller and Diekema, 2007; Diekema
et al., 2012; Rodrigues et al., 2014). Cryptococcus neoformans is
another opportunistic pathogen of clinical relevance, especially
among HIV/AIDS patients. Cryptococcal meningitis is the most
important cause of death from HIV-related fungal infection
worldwide (Park et al., 2009). The estimated yearly incidence
of cryptococcal meningitis is almost one million cases, causing
625,000 deaths (Park et al., 2009). In addition, Candida species
and C. neoformans can form biofilms on abiotic and biotic
surfaces (Mayer et al., 2013; Martinez and Casadevall, 2015). Of
particular interest is the formation of biofilms by C. albicans,
which confers specialized properties to the microorganism
that complicate treatment, such as the increased resistance to
antimicrobial drugs and the ability to evade the host immune
system, among others (Finkel and Mitchell, 2011; Fanning and
Mitchell, 2012). Another problem regarding fungal infections
is the rising of resistance to currently available antifungal
drugs (Pan et al., 2012; Pfaller, 2012; Arendrup, 2013). This
is compounded by the intrinsic resistance of some fungi to
antifungals, such as C. neoformans to echinocandins and
C. glabrata to azoles (Sable et al., 2008; Pfaller, 2012; Paul and
Moye-Rowley, 2014).
In this scenario, there is a concrete need for new antifungals,
and antimicrobial peptides (AMPs) have been promoted as
promising in that regard (Hancock and Sahl, 2006), considering
their low molecular masses and lower potential to induce
resistance (Mookherjee and Hancock, 2007; Huang et al., 2010).
A great number of peptides are present in scorpion venom.
They can be classified as disulfide-bridged peptides or non-
disulfide-bridged peptides (NDBPs), the latter being the major
component of their venom (Almaaytah and Albalas, 2014;
Harrison et al., 2014; Ortiz et al., 2015). Most have similar
physicochemical characteristics, such as a cationic character and
structural flexibility. NDBPs present diverse biological activities,
including antimicrobial, cytolytic, immunomodulatory,
antitumor, and bradykinin-like potentiation effects (Zeng
et al., 2005; Almaaytah and Albalas, 2014; Ortiz et al., 2015).
In the present work, we evaluated the antifungal activity of
peptides previously obtained by transcriptomic approaches from
venom glands of three scorpion species (Silva et al., 2009). We
classified them according to the rules proposed by Zeng et al.
(2005), who group scorpion NDBPs in six subfamilies based on
their pharmacological action, length and structural similarity.
The peptides presented here belong to subfamilies 3, 4, and 5
and their activity will be discussed following this classification.
Some AMPs are presented here for the first time, among them
five peptides from the venom of the scorpion Tityus obscurus
corresponding to the first AMPs characterized in this species.
MATERIALS AND METHODS
cDNAs Encoding Putative Antimicrobial
Peptides
Different cDNAs encoding putative AMPs from the venom gland
of scorpions T. obscurus, Tityus costatus, Hadrurus gertschi,
and Opisthacanthus cayaporum were characterized by expressed
sequence tag (EST). The amino acid sequences deduced from
ESTs as described in literature (Diego-Garcia et al., 2005;
Schwartz et al., 2007; Silva et al., 2009; Guerrero-Vargas et al.,
2012) were considered to obtain the synthetic peptides as
specified bellow (Table 1).
Comparative analyses of amino acids sequences were
performed employing the Basic Local Alignment Search Tool
(BLAST1) and Collection of Anti-Microbial Peptides (CAMP2)
databases to identify peptides with at least 40% of identity to
our queries sequence and to which antimicrobial activity was
previously determined. The multiple sequence alignments were
done using the M-Coffee tool3 on the sequences identified in the
previous step, and the consensus sequences were represented as
a sequence logo, generated at Weblogo web server4.
Chemical Peptide Synthesis
Peptides were chemically synthesized using FMOC-Butila
(AminoTech Pesquisa e Desenvolvimento LTDA, Brazil), and
further purified by reverse-phase high performance liquid
chromatography (HPLC). Peptides ToAP1, ToAP2S1, ToAP3,
NDBP-4.23, ToAP4, and NDBP-5.7 were synthesized with
C-terminal amidation. To assess the purity and sequence
correctness, peptides were submitted to matrix-assisted laser
desorption/ionization time of flight mass spectrometry (MALDI-
TOF/TOF MS; UltraFlex III, Bruker Daltonics, Germany),
under reflector (MS) and LIFTTM (MS/MS) positive modes.
Matrix solution was prepared using 5.0 mg of α-cyano-
4-hydroxycinnamic acid (Sigma, USA) and solubilized with
250 µL of acetonitrile, 200 µL of deionized water, and with
50 µL of an aqueous trifluoroacetic acid solution (at 3% by
volume). The aqueous solution of the peptide was mixed with
a saturated matrix solution (1:3 peptide/matrix) and air-dried.
The monoisotopic molecular mass of the ion corresponding to
the peptide of interest was determined by the ratio between
m/z peaks in the spread profile (m/z ratio from 600 to
3,000). Additionally, interpretation of the MS/MS mass spectra
1http://blast.ncbi.nlm.nih.gov/Blast.cgi
2http://www.camp.bicnirrh.res.in/
3http://tcoffee.crg.cat/apps/tcoffee/do:mcoffee
4http://weblogo.berkeley.edu/logo.cgi
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TABLE 1 | Sequence of chemically synthesized peptides obtained from scorpion venom cDNA library sequencing.
Peptide Subfamily UniProt entry Sequence Species
ToAP2 3 LT576030 FFGTLFKLGSKLIPGVMKLFSKKKER T. obscurus
ToAP2S1 3 FFGTLFKLLSKLIPGLMKLFSKLLER-NH2 Modified
Con10 3 C5J897 FWSFLVKAASKILPSLIGGGDDNKSSS O. cayaporum
ToAP3 4 ∗ FIGMIPGLIGGLISAIK-NH2 T. obscurus
NDBP-4.23 4 Q5G8B5/S6D3A7 FLGMIPGLIGGLISAFK-NH2 T. costatus; T. obscurus
ToAP1 4 LT576029 FIGMIPGLIGGLISAFK-NH2 T. obscurus
ToAP4 4 ∗ FFSLIPSLIGGLVSAIK-NH2 T. obscurus
NDBP-5.6 5 P0C8W2 FIFDLLKKLV H. gertschi
NDBP-5.7 5 C5J886 ILSAIWSGIKSLF-NH2 O. cayaporum
NDBP-5.8 5 C5J887 GILGKIWEGVKSLI O. cayaporum
ToAcP ∗∗ LT576031 EEDDLLGFSEEDLKAIKEHRAKNA-NH2 T. obscurus
∗Accession number recently requested; ∗∗subfamily not designated. NDBP, non-disulfide-bridged peptide.
and de novo sequencing of peptides was performed using
the FlexAnalysis 3.0 software (Bruker Daltonics, Germany).
Throughout the experiment, the stability of each peptide was
reevaluated using the same mass spectrometry parameters
detailed above. Only samples containing more than 95% of
the peptide (high purity) were used for biological experiments.
Peptides were stored at −20◦C and dissolved in Milli-Q water
before each experiment.
In silico Analysis of Putative Secondary
Structure and Peptides Physicochemical
Properties
The putative secondary structures and the α-helix content
(%) were predicted using the software PHD as described
previously (Guo et al., 2013)5. The hydrophobicity and the helical
hydrophobic moment of the peptides were determined in the
HeliQuest web server6. Other physicochemical properties were
determined by ProtParam tool7 (Wilkins et al., 1999). Helical
wheel projections were generated at the respective web server8.
Fungal Strains and Growth Conditions
Candida albicans strain SC 5314 (ATCC MYA-2876) was
provided by Dr. Joshua Nosanchuk (New York, NY, USA).
C. glabrata ATCC 90030, C. parapsilosis ATCC 22019,
and C. tropicalis ATCC 750 were provided by Dr. Érika
Kioshima (Universidade Estadual de Maringá, Paraná, Brazil).
C. neoformans var. grubii strain H99 (serotype A, ATCC
208821) was provided by Dr. John Perfect (Durham, NC, USA).
C. neoformans var. neoformans B3501 (serotype D, ATCC 34873)
was obtained from ATCC (Manassas, VA, USA). All strains were
stored as frozen stocks in 35% glycerol at −80◦C. Before each
experiment, all Candida spp. strains were grown in Sabouraud’s
dextrose broth overnight at 30◦C with agitation. C. neoformans
strains were grown in the same conditions for 24 h. Fungal
cells were collected by centrifugation, washed three times in
5https://npsa-prabi.ibcp.fr/cgi-bin/npsa_automat.pl?page=/NPSA/npsa_phd.html
6http://heliquest.ipmc.cnrs.fr/cgi-bin/ComputParamsV2.py
7http://web.expasy.org/protparam
8http://rzlab.ucr.edu/scripts/wheel/wheel.cgi
phosphate buffered saline (PBS) (137 mM NaCl, 2.7 mM KCl,
10 mM Na2HPO4, 2 mM KH2PO4) and inoculated in Roswell
Park Memorial Institute (RPMI) 1640 medium supplemented
with L-glutamine and buffered to pH 7.0 with 165 mM 3-(N-
morpholino)propanesulfonic acid for experiments described
below.
Antifungal Assay
In vitro antifungal assays were performed according to broth
microdilution susceptibility test from Clinical and Laboratory
Standards Institute (CLSI) M27-A3 guidelines with some
modifications. Briefly, twofold serial dilutions of each peptide
were prepared in 96-well polystyrene microplates to a final
volume of 50 µL. Amphotericin B (Amp B; A2942, Sigma-
Aldrich), a known antifungal drug, was used as a positive control.
Final concentrations of each peptide and Amp B ranged from
100 to 0.78 µM and 16 to 0.03 µg/mL, respectively, except in
tests with C. glabrata and C. parapsilosis, where the final peptide
concentration ranged from 400 to 0.78 µM. In each plate, wells
were included without peptide as a growth control. Then, 50 µL
of the adjusted inoculum in RPMI-1640 medium were added to
each well to a final concentration of 2× 103 cells/mL for Candida
spp. and 104 cells/mL for C. neoformans strains. The plates were
incubated at 37◦C for 24 and 48 h, respectively. The strains
of C. neoformans were also incubated with shaking (200 rpm).
The minimum inhibitory concentration (MIC) was defined
as the lowest AMP concentration that completely inhibited
visible fungal growth at the end of the incubation period. The
experiments were performed at least three times on separate
dates.
Hemolytic Assay
Considering the potential use of the AMPs as treatment against
pathogens, even if in a more distant future, some of their
properties against host cells should be addressed. To achieve this
goal, we have performed hemolytic assay to evaluate if these
molecules are toxic or harmless to red blood cells. Further, we
have also tested the possible cytotoxicity of those peptides against
other mammalian cell types by following the cell viability score
after treatment. The solution of human red blood cells was treated
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with the peptide at levels ranging from 100 to 0.78 µM. Whole
human blood was collected from healthy donors in vials with
ethylenediaminetetraacetic acid (EDTA). The red blood cells were
separated by centrifugation and resuspended in PBS. After the
centrifugation (800 g, 5 min at 4 ± 1◦C) the supernatant was
removed and the red blood cells pellet was resuspended to a
3% hematocrit in sterile water (considered as 100% hemolysis)
and PBS (taken as blank for spectrophotometric measurement).
Fifty microliters of the 3% cell suspension in PBS were added
to different final concentrations of the peptide (v/v) in a 96-well
polystyrene microplate and then incubated for 1 h (Nahar et al.,
2008; Zhao et al., 2009; Qi et al., 2010). The microplates were
centrifuged and the supernatant was collected and analyzed at
540 nm using a microplate spectrophotometer. The percentage
of hemolysis was calculated relative to the positive control as
performed by Nahar et al. (2008). The procedures were approved
by the Ethics Committee on Human Research of Faculty of
Medicine/University of Brasília (UnB) and conform to FDA
standards (UnBDoc no. 66704/2016).
Cytotoxic Test Using Peritoneal
Macrophages
BALB/c mice were injected with thioglycolate 72 h before
peritoneal macrophages were harvested. They were diluted to
a concentration of 106 cell/mL in RPMI-1640 supplemented
with penicillin/streptomycin (100 U/mL, 100 g/mL), 2 mM
L-glutamine, 2 mM non-essential amino acids, 1 mM sodium
pyruvate (all reagents from Sigma-Aldrich, St Louis, MO, USA)
and 10% fetal bovine serum (FBS), and incubated in 96-well
polystyrene microplates at 37◦C, 5% CO2 for 24 h. The peptides
were added then and cells were further incubated for 24 h
as described previously (Cruz et al., 2005). Three independent
experiments were performed. Cytotoxic activity was evaluated by
the release of cytoplasmic enzyme lactate dehydrogenase due to
cell lysis using the Cytotox kit (Promega). Briefly, at the end of
the incubation period, supernatants were collected, the adhered
cells were washed and the toxicity was determined according to
the manufacturer’s protocol. The procedures were approved by
the Ethics Committee on Animal Research of Institute of Biology
(UnBDOC 52657/2011)/University of Brasília (UnB).
Effects of Peptides on Candida albicans
Biofilms
The effects of the peptides NDBP-4.23, ToAP1, ToAP2, and
NDBP-5.7 on C. albicans biofilms were analyzed according to
the protocol described by Pierce et al. (2008). Briefly, C. albicans
SC 5314 (106 cells/mL) was grown on 96-well polystyrene
microplates and 4 h after seeding the peptides or Amp B
were added to assess their effects on the first step of biofilm
formation, the initial cell adherence. After 24 h of treatment,
biofilm formation was measured by the metabolic assay based
on the reduction of 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-
2H-tetrazolium-5-carboxanilide (XTT). For the purpose of
investigating effects of peptides on mature biofilms, the Candida
cells were allowed to grow for 24 h prior to addition of the
peptides or Amp B and the XTT assay was performed in the same
way. All results were analyzed for statistical significance using
analysis of variance (ANOVA) followed by Tukey post-test using
GraphPad Prism 6 and expressed in terms of biofilm viability
as XTT-readings percentage normalized by the control groups.
Each compound was tested in triplicate and the experiments were
performed at least twice on separate dates.
Circular Dichroism
Circular dichroism (CD) assays were carried out using Jasco J-
815 spectropolarimeter equipped with a Peltier-type temperature
controller. Peptides (0.2 mg/mL) were analyzed in water at 37◦C
in absence or the presence of trifluoroethanol (TFE) (10, 30,
and 50%). The mean spectrum of three consecutive experiments
was corrected for the baseline buffer contribution. The observed
ellipticities were converted into molar ellipticity ([θ]) based on
molecular mass per residue of 115 Da (Adler et al., 1973). The α
helix secondary structure content (f θ) was estimated considering
the values of [θ]208 nm as a function of TFE concentration using
the following equation (Greenfield and Fasman, 1969):
fH = ([θ]208 − 4000)
(−33000 − 4000)
RESULTS
In silico Prediction of Major
Physicochemical Properties and
Secondary Structure of Peptides
The primary structures of ToAP2, ToAP1, ToAP3, ToAP4, and
ToAcP peptides from T. obscurus were used as queries on
BLAST. Data analysis revealed that ToAP2 is similar to peptides
previously described as belonging to NDBP subfamily 3 and to
AMPs from ant venom (Figures 1A,B). ToAP1, ToAP3, and
ToAP4 showed similarity to AMPs belonging to NDBP subfamily
4 (Figures 1C,D). ToAP4 also has 100% identity to putative
AMP clone 6 from T. costatus [UniProt: Q5G8B3]. ToAcP did
not show similarity to any AMPs described before and shares
90% identity to Toxin Tp3 [UniProt: P0DL22], a peptide from
Tityus pachyurus with no toxicity to mammalian cells and without
known biological activity (Barona et al., 2006). The result of
these analyses indicates that peptide ToAP2 belong to NDBP
subfamily 3 and ToAP1, ToAP3, ToAP4 belongs to NDBP
subfamily 4.
The results of in silico secondary structure and
physicochemical property prediction for the peptides are
summarized in Table 2. Except for ToAP2 and ToAcP, which
have net charges at pH 7.0 of +6 and −4, respectively, all others
showed a net charge of +1. All peptides have a predicted helical
content of at least 53.85% and, except for ToAcP, had positive
hydrophobicity values, which means that in theory they are
slightly hydrophobic. ToAP2S1, an analog from ToAP2, had
different physicochemical parameters. Its net charge was reduced
from +6 to +4 as a result of the substitution of two lysines for
leucines; and both its hydrophobicity and hydrophobic moment
were increased. ToAP2S1 also had its predicted helical content
increased from 57.69 to 88.46% relative to its prototype ToAP2.
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FIGURE 1 | Comparative analysis of ToAP2, ToAP1, ToAP3, ToAP4 against previously described AMPs. Conserved amino acid residues are marked bold.
Asterisks indicate peptides with amidated C-termini. (A,B) Multiple sequence alignment of ToAP2 mature peptide with known AMPs from scorpion and ant venoms
such as Ponericin-W-like 32.1 [UniProt: P0CI91], Ponericin-W-like 32.2 [UniProt: P0CI92], Css54 [UniProt: P0DL41], Pandinin 2 [UniProt: P83240], Heterin-2
[UniProt: A0A0C4G5K0], Ponericin-W1 [UniProt: P82423], Ponericin-W2 [UniProt: P82424], and Ponericin-W5 [UniProt: P82427] and their consensus sequence
logo. (C,D) Multiple sequence alignment of ToAP1 mature peptide with known antimicrobial peptides from scorpion venom such as NDBP-4.23 [UniProt:
Q5G8B5/S6D3A7], Mucroporin [UniProt: B9UIY3], Imcroporin [UniProt: C7B247], Stigmurin [GenBank: JK483709], AP6_TITCO [UniProt: Q5G8B3], TsAP-1
[UniProt: S6CWV8], AamAP1 [UniProt: G8YYA5], AamAP2 [UniProt: G8YYA6], BmKb1 [UniProt: Q718F4], and AcrAP1 [UniProt: A0A0A1I6E7] and their consensus
sequence logo.
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TABLE 2 | Peptide sequences, putative secondary structure, and physicochemical properties.
Peptide Sequence and
secondary structure
Length α-helix (%) Hydrophobicity Hydrophobic moment Net charge
ToAP2 FFGTLFKLGSKLIPGVMKLFSKKKER
ccchhhhcccchhhhhhhhhhhcccc
26 57.69 0.443 0.460 +6
ToAP2S1 FFGTLFKLLSKLIPGLMKLFSKLLER-NH2
cchhhhhhhhhhhhhhhhhhhhhhhc
26 88.46 0.734 0.672 +4
Con10 FWSFLVKAASKILPSLIGGGDDNKSSS
chhhhhhhhhhhhhhhhcccccccccc
27 59.26 0.435 0.331 +1
ToAP1 FIGMIPGLIGGLISAFK-NH2
ccchhhhhhhhhhhccc
17 64.71 0.906 0.597 +1
ToAP3 FIGMIPGLIGGLISAIK-NH2
cccchhhhhhhhhhhcc
17 64.71 0.907 0.597 +1
NDBP-4.23 FLGMIPGLIGGLISAFK-NH2
ccchhhhhhhhhhhhhc
17 76.47 0.908 0.594 +1
ToAP4 FFSLIPSLIGGLVSAIK-NH2
cccchhhhhhhhhhhhc
17 70.59 0.895 0.592 +1
NDBP-5.6 FIFDLLKKLV
chhhhhhhcc
10 70.00 0.895 0.715 +1
NDBP-5.7 ILSAIWSGIKSLF-NH2
ccchhhhchhhcc
13 53.85 0.926 0.668 +1
NDBP-5.8 GILGKIWEGVKSLI
chhhhhhhhhhhhc
14 85.71 0.686 0.680 +1
ToAcP EEDDLLGFSEEDLKAIKEHRAKNA-NH2
ccccccccchhhhhhhhhhhhhcc
24 54.17 −0.016 0.248 −4
NDBP, non-disulfide-bridged peptide; the letter “c” represents random coil and “h” represents α-helix; the putative secondary structures and the α-helix content (%) were
predicted using the software PHD (Guo et al., 2013); the hydrophobicity and the helical hydrophobic moment of the peptides were determined in the HeliQuest web
server; length and net charge properties were determined by ProtParam tool.
Helical wheel projections predict that ToAP2, ToAP2S1, ToAP1,
ToAP3, and ToAP4, once adopting a helical conformation, are
amphipathic peptides, thus presenting distinct hydrophobic
and hydrophilic faces (Figure 2). ToAcP, however, presents
only a hydrophilic face. The lack of a distinct hydrophobic face
compromises its amphipathicity.
Antimicrobial Assay
Antifungal assays were performed against different species of
Candida and C. neoformans (Table 3).
Seven peptides were active against Candida spp. and
C. neoformans. ToAP2 and Con10, both from NDBP subfamily 3,
had antifungal activity against all strains tested with MICs values
ranging from 3.12 to 200 µM and 12.5 to 200 µM, respectively.
Among peptides from NDBP subfamily 4, only ToAP4 has
not shown antifungal activity in the tested concentrations (data
not shown). The other peptides from this subfamily presented
antimicrobial activity against all Candida spp. and C. neoformans
in the same MIC range (6.25–200 µM), except for C. glabrata,
which is insensitive to them. C. glabrata is also resistant to
all peptides from NDBP subfamily 5. Among those subfamily
peptides, NDBP 5.7 presented antifungal activity with MIC values
ranging from 12.5 to 25 µM and NDBP 5.8 inhibited the growth
of pathogens tested at concentrations ranging from 50 to 200µM.
NDBP-5.6 and ToAcP did not present antifungal activity in this
assay (data not shown).
Since ToAP2 showed the lower MIC against all pathogens
tested in this work, derivatives of its structure were produced
in order to increase the α-helical content. The modified peptide,
ToAP2S1 (Table 1) was synthesized and tested against two
Candida species (C. albicans and C. glabrata) and C. neoformans
H99. ToAP2S1 did not show antifungal activity in the tested
concentrations (data not shown), demonstrating that the changes
in peptide sequence abolished antifungal activity relative to the
reference peptide.
Based on results from antimicrobial assay, we decided to
proceed only with those peptides (at least one per family) that
showed best antimicrobial activity.
Hemolysis and Cytotoxicity Assays
The hemolytic activities of peptides ToAP2, NDBP-4.23, ToAP1,
and NDBP-5.7 were evaluated against human erythrocytes
(Figure 3). ToAP2S1 was also tested to evaluate if it also has
lost its hemolytic activity. NDBP-4.23 and ToAP1 might be
considered of interest to future studies, because in all the tested
concentrations their hemolysis curves were significantly lower
than 50% of hemolysis (Conlon et al., 2007; Thaker et al.,
2011; Figures 3B,C). However, NDBP-5.7 presents a hemolysis
percent higher than 50% in concentrations up to 50 µM
(Figure 3D). Comparing the original peptide ToAP2 and the
modified ToAP2S1, the last one shows a higher hemolysis curve
with concentrations up to 25µM while the ToAP2 maintained its
curve above 50% of hemolysis (Figure 3A).
Toxicity to mammalian cells was further evaluated by
assessing the viability of murine peritoneal macrophages in the
presence of the peptides (Figure 4). The threshold of acceptable
cytotoxicity was set at 50% viability as postulated elsewhere
(Thaker et al., 2011; Zhao et al., 2012). In conformity with the
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FIGURE 2 | Helical wheel projections of the α-helical structured peptides. The projections were generated at the web server for this tool
(http://rzlab.ucr.edu/scripts/wheel/wheel.cgi). Diamonds, hydrophobic residues; circles, hydrophilic residues, non-charged; pentagons, positively charged residues;
triangles, negatively charged residues.
TABLE 3 | Inhibitory concentrations of different peptides against Candida spp. and two Cryptococcus neoformans strains.
Peptide Minimum inhibitory concentration (µM)
C. albicans
(SC5314)
C. tropicalis
(ATCC 750)
C. parapsilosis
(ATCC 22019)
C. glabrata
(ATCC 90030)
C. neoformans
(H99 serotype A)
C. neoformans
(B3501 serotype D)
ToAP2 12.5 3.12 50 200 12.5 6.25
Con10 100 12.5 200 200 50 25
ToAP3 25 12.5 100 >400 100 25
NDBP-4.23 50 6.25 100 >400 25 12.5
ToAP1 50 12.5 200 >400 25 12.5
NDBP-5.7 25 25 >400 >400 25 12.5
NDBP-5.8 100 25 200 >400 100 50
Amp B 1.08 2.16 2.16 1.08 0.27 0.135
NDBP, non-disulfide-bridged peptide; Amp B, amphotericin B. The values of 0.135, 0.27, 1.08 and 2,16 µM of Amp B are equivalent to 0.125, 0,25, 1 and 2 µg/mL of
Amp B respectively.
hemolytic test, ToAP2 and NDBP-4.23 in concentrations below
6.25 and 25 µM, respectively, have shown low cytotoxicity
(Figures 4A–C). For ToAP1 and NDBP-5.7, peritoneal
macrophages displayed higher viability in the whole range
of peptide concentrations (Figures 4B–D). The difference in
the hemolytic curves between ToAP2 and its analog (ToAP2S1)
could be explained by the higher hydrophobicity of ToAP2S1
(Table 2) and consequent tendency to self-associate. Chen et al.
Frontiers in Microbiology | www.frontiersin.org 7 November 2016 | Volume 7 | Article 1844
fmicb-07-01844 November 16, 2016 Time: 14:6 # 8
Guilhelmelli et al. Scorpion’s AMPs against Pathogenic Fungi
FIGURE 3 | Hemolytic activity of peptides against human erythrocytes. (A) ToAP2 and ToAP2S1, (B) ToAP1, (C) NDBP-4.23, and (D) NDBP-5.7.
(2007) demonstrated that there is an optimal hydrophobicity
window for AMPs, below which antimicrobial activity can be
lost and above which self-association becomes highly likely.
Peptide aggregation prevents penetration through the capsule
and cell wall of microorganisms (Jiang et al., 2008). However,
the higher hydrophobicity does not affect their activity on the
eukaryotic membrane (Chen et al., 2007), which explains the
lower antifungal activity and the higher hemolytic activity of the
modified ToAP2S1, respectively.
Effects of the Peptides on Candida
albicans Biofilms
We visualized C. albicans biofilms at 4 and 24 h by fluorescence
microscopy using uvitex 2B, which binds chitin in the fungal
cell wall, and they exhibited typical features of mature biofilms,
including a basal layer of yeast cells and a thicker layer of yeast
and hyphae cells (Supplementary Material). This structure was
very similar to the morphology of C. albicans biofilms presented
in other works in the literature (Pierce et al., 2014, 2015).
Additionally, the inhibition values of biofilms by Amp B were
similar to those found by Ramage et al. (2001, 2002).
The effects of ToAP2, NDBP-4.23, ToAP1, and NDBP-5.7
on C. albicans biofilms were evaluated on the initial adherence
step (Figure 5A) and on the mature biofilm (Figure 5C).
As a control, the effect of Amp B was also shown at both
time points (Figures 5B,D), with a reduction of at least 80%
in biofilm viability at 0.25 µg/mL for the initial adherence
and 2 µg/mL for the three-dimensional architecture. All the
peptides were active against biofilm formation, albeit at a higher
concentration compared to what was observed against planktonic
cells (100 µM for the initial adherence and 400 µM for the
three-dimensional architecture). ToAP2 was the most active
peptide at the two different stages of biofilm formation, with
a lower effective concentration than the others (25 µM for
the initial adherence and 200 µM for the three-dimensional
architecture).
Circular Dichroism
The secondary structures of native (ToAP2) and modified
(ToAP2S1) peptides were assessed by CD spectroscopy. FAR-UV
CD spectra of ToAP2 in water at 37◦C revealed a typical
disordered structural pattern (Figure 6A). At increasing
concentrations of 10, 30, and 50% TFE (v/v), a red shift
from 200 to 208 and 222 nm and increased negative dichroic
signals were observed (Figure 6A). These results show that
ToAP2 lacks secondary structure in aqueous environments
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FIGURE 4 | Cytotoxicity of peptides against peritoneal macrophages of BALB/c mice. (A) ToAP2, (B) ToAP1, (C) NDBP-4.23, and (D) NDBP-5.7.
and has a tendency to adopt an α-helical pattern at aqueous
environments in the present of the co-solvent TFE (Table 4).
In contrast, an α-helical conformation was observed for the
modified peptide ToAP2S1 in water at 37◦C even in the absence
of TFE. In the presence of 10, 30, and 50% TFE, intense
negative dichroic bands at 208 and 222 nm were observed
(Figure 6B), which are compatible with higher α-helix content
(Table 4). Fractional helicity of peptides in water and TFE
environments was calculated considering the molar ellipticity at
208 nm (Table 4). There was an increased α-helix content for
both peptides as a function of TFE, with ToAP2S1 presenting
approximately 17% of α-helix in water in the absence of the
co-solvent.
DISCUSSION
We have witnessed a steady increase in the incidence of systemic
fungal diseases in the last decades, partially due to medical
advances and the rise of immunosuppressive diseases. Although
antifungal therapy is somewhat efficient, there are only four
classes of agents, many of which have significant side effects.
In addition, there is an increasing number of fungal species
with natural or acquired resistance to these drugs. For instance,
the most recent class of antifungals, the echinocandins, was
discovered in the seventies and only became available for clinical
therapy in 2002. Since then, the search for new antifungal targets
and potential drugs for more efficient and less toxic treatments
has been an ongoing work. AMPs are attractive alternatives as
antifungal drugs and here we describe seven scorpion venom-
derived peptides with promising antimicrobial activity against
Candida spp. and/or C. neoformans strains, all of which are major
fungal pathogens.
Regardless of the strain, ToAP2, the most cationic peptide,
showed the lowest inhibitory concentrations in our tests. ToAP2
and Con10 exhibited sequence similarity to Pandinin 2, for
which anti-C. albicans activity has been described with a MIC of
19.1 µM (Corzo et al., 2001). In contrast, while ToAP2 presented
MIC values around this range, Con10 showed much higher values
for C. albicans and most of the other tested strains. Despite
the similarity, Con10 has lower net positive charge (+1) than
Pandinin 2 (+3). Conversely, ToAP2 physicochemical properties
are more similar to those of Pandinin 2: its net positive charge
is +6. Several studies have shown that analog of AMPs with
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FIGURE 5 | Effects of the peptides ToAP2, NDBP-4.23, ToAP1, NDBP-5.7, and amphotericin B on C. albicans biofilm formation. Effects of the peptides
(A) and Amp B (B) on the initial adherence and effects of the peptides (C) and Amp B (D) on the mature stage. Results are expressed in terms of biofilm viability as
XTT-reduction assay readings percentage, normalized by the control groups. The experiments were performed at least twice on different days. Statistical analyses:
ANOVA and Turkey post-test (∗∗∗∗P ≤ 0.0001; ∗∗∗P ≤ 0.001; ∗∗P ≤ 0.01; ∗P ≤ 0.05). Mean ± SEM.
amino acids substitutions to increase positive net charge had
better antifungal activity (Nikawa et al., 2004), which may explain
the poor antifungal activity of Con10 relative to ToAP2 and
Pandinin 2.
We also analyzed the secondary structures of the peptides
in water and in a mimetic membrane environment (aqueous
co-solvent TFE) by CD spectroscopy. The FAR-UV CD spectra
showed that ToAP2 and its modified version ToAP2S1 have
typical disordered and α-helical structures in water at 37◦C,
respectively. There was an increase in α-helix content for
both peptides as a function of TFE concentration (Table 4),
indicating the potential of these molecules to interact with the
cellular membrane, a classical feature of α-helical AMPs. Stability
assays also showed that the non-modified peptide presented
lower α-helix content and lower stability than the modified
peptide. These observations may indicate that net charge is an
important parameter for antifungal activity as well as to the
conformation changes induced by the interaction with the fungal
membrane.
ToAP1 and ToAP3 share similarity with AamAP1, AamAP2,
and AcrAP1 (Figure 1), peptides that have already been
documented as having anti-C. albicans activity (Almaaytah et al.,
2012; Du et al., 2014). Interestingly, ToAP1 and ToAP3 only
differ at one residue at position 16, respectively a Phe and an
Ile. While ToAP3 has better anti-Candida spp. activity, ToAP1
showed better activity against C. neoformans (Table 3). This
result suggests that Phe16 in ToAP1 could be essential for anti-
C. neoformans activity. The lack of activity of ToAP4 against the
fungal strains tested in our assay condition is worth noting, in
spite of its 82.3% identity with Stigmurin (Figure 1), a peptide
from Tityus stigmurus that inhibits the growth of C. albicans and
C. glabrata with MIC values of 34.8µM and 69.5µM, respectively
(de Melo et al., 2015). This difference could be due to different
methods used to evaluate antifungal activity or the difference in
sequence itself. More studies are needed to evaluate this.
NDBP-5.7 and NDBP-5.8 showed high similarity to IsCT,
IsCT2, and Patinin3, peptides with antifungal activity against
C. albicans and C. tropicalis (Dai et al., 2002; Zeng et al.,
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FIGURE 6 | FAR-UV CD spectra of peptides in water and 10, 30, 50%
TFE. (A) Spectra of ToAP2 presenting a red shift from 200 nm to 208 and
222 nm in the presence of TFE; (B) Spectra of ToAP2S1 showing an increase
of the dichroic signals at 208 and 222 nm from water to TFE.
TABLE 4 | α-Helix content (%) of peptides in water, and TFE at 10, 30, and
50%.
Solvent α-Helix content (%) of peptides
ToAP2 ToAP2S1
Water 9.8 16.5
TFE 10% 12.9 22.9
TFE 30% 20.8 24.3
TFE 50% 25.8 24.7
2013). Considering that the C-terminal amidation modifies the
net positive charge and stabilizes peptide structure, improving
antimicrobial activity (Huang et al., 2010), the lack of this
chemical group may explain the lower activity of NDBP-
5.8 against the tested microorganisms (Tables 2 and 3). By
its turn, the lack of antifungal activity of ToAcP probably
could be explained by its net negative charge, which causes
electrostatic repulsion from the microbial plasma membrane (van
der Weerden et al., 2013).
Among the tested Candida species, C. glabrata was the most
resistant, with inhibitory concentrations higher than 400 µM
for all peptides. This result is in accordance with the literature
describing the high intrinsic resistance shown by this species
to most antifungal drugs, as well as to Histatin 5, one of the
best candidacidal peptides already described (Sobel, 2006; Tati
et al., 2013; Rodrigues et al., 2014). Conversely, C. tropicalis
was the most susceptible organism among Candida species. As
shown in Table 3, the AMPs exhibited their lowest inhibitory
concentrations against C. tropicalis, in contrast with its described
high virulence, associated infection mortality rates, and resistance
to amphotericin B (CLSI M27-A3 protocol (Colombo et al.,
2007). Consequently, the peptides tested in this work are
promising candidates for the development of treatments for
C. tropicalis infection.
With regard to the effects of AMPs against C. neoformans,
the B3501 strain (serotype D) was more sensitive to the
scorpion peptides than the H99 strain (serotype A). This is in
accordance with the previously described higher susceptibility
of this serotype to amphotericin B (Thompson et al., 2009).
C. neoformans has a negatively charged polysaccharide capsule
that is one of the most important virulence factors of this yeast
(McFadden et al., 2006). Its thickness varies according to strain,
with strain B3501 presenting a thicker capsule than H99 under
non-inducing conditions. Therefore, it is possible that the capsule
exerts an electrostatic attraction effect on cationic AMPs, which
may explain the higher susceptibility of strain B3501. Similarly,
susceptibility of C. neoformans to polymyxin B was previously
reported to be dependent on fungal capsule thickness (Zhai and
Lin, 2013).
In addition to the effects on planktonic cells described above,
we also analyzed their action against C. albicans biofilms. Biofilms
represent a great health concern due to their intrinsic resistance
to antimicrobial treatment and to the patient immune response.
The resistance involves different factors like overexpression of
drug resistance genes and impairment of drug penetration due
the thickness of the extracellular matrix. All peptides tested
(ToAP2, NDBP-4.23, ToAP1, and NDBP-5.7) reduced biofilm
on both the initial cell adherence stage and the mature phase,
albeit at higher concentration ranges relative to planktonic
cells, which holds true for all antimicrobials. Again, ToAP2
was the most active peptide at the two different stages of
biofilm formation, presenting a lower effective concentration
than the other peptides (25 µM for the initial adherence and
200 µM for the three-dimensional architecture). These results
are encouraging, since the peptides showed an antifungal effect in
different phases of the biofilm process with lower concentrations
than expected for prospective antifungals (100–1,000 times
higher than concentrations used against planktonic cells (Pierce
et al., 2008). Furthermore, hemolysis and cytotoxicity assays
showed promising results regarding the selective toxicity of the
tested peptides. Most of the tested peptides can be considered of
interest for future studies, as they caused hemolysis of less than
50% of erythrocytes and more than 50% of murine peritoneal
macrophages remained viable in their presence.
In summary, we described seven scorpion venom-derived
AMPs with antifungal activity against cells of Candida spp. and
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C. neoformans and against C. albicans biofilms, including two
novel molecules. This is the first report of scorpion-derived AMPs
against C. neoformans and our results underscore the potential
of scorpion-venom as a source of antimicrobials. The observed
effects of the described peptides during and after C. albicans
biofilm formation highlight the antimicrobial potential of these
molecules in the face of the huge impact of biofilm-derived
infections in hospitalized patients. Further characterization of
their mechanisms of action and interaction with available
antifungals, followed by molecular optimization to reduce their
toxicity to host cells and increase antimicrobial activity are need
to fully clarify their real potential as antifungals.
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